Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03929666
Title A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Zymeworks Inc.

colorectal cancer

gastroesophageal adenocarcinoma

biliary tract cancer


Cisplatin + Gemcitabine

Cisplatin + Fluorouracil + ZW25

Capecitabine + Oxaliplatin + ZW25

Fluorouracil + Leucovorin + Oxaliplatin + ZW25

Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + ZW25

Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.